EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib

被引：15
|
作者：
Tao, Zhonfei [1 ,2 ,3 ,5 ]
Liu, Bingcheng [1 ,2 ,3 ]
Zhao, Yaozhong [1 ,2 ,3 ]
Wang, Ying [1 ,2 ,3 ]
Zhang, Rongli [1 ,2 ,3 ]
Han, Mingzhe [1 ,2 ,3 ]
Zhang, Li [1 ,2 ,3 ]
Li, Chengwen [2 ,3 ,4 ]
Ru, Kun [2 ,3 ,4 ]
Mi, Yingchang [1 ,2 ,3 ]
Wang, Jianxiang [1 ,2 ,3 ,5 ]
机构：
[1] Chinese Acad Med Sci, Dept Clin Hematol, Inst Hematol, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China
[3] Peking Union Med Coll, Tianjin 300020, Peoples R China
[4] Chinese Acad Med Sci, Dept Hemopathol, Inst Hematol, Tianjin 300020, Peoples R China
[5] Chinese Acad Med Sci, State Key Lab Expt Hematol, Inst Hematol, Tianjin 300020, Peoples R China
来源：
LEUKEMIA RESEARCH | 2014年 / 38卷 / 09期
基金：
中国国家自然科学基金;
关键词：
EUTOS; Chronic myeloid leukemia; Complete cytogenetic response; Overall survival; Progression free survival; Prognosis; PATIENTS RECEIVING IMATINIB; TYROSINE KINASE INHIBITORS; EUROPEAN TREATMENT; PROGNOSTIC SCORE; FOLLOW-UP; CML; FRONTLINE; RECOMMENDATIONS; RESISTANCE; THERAPY;
D O I：
10.1016/j.leukres.2014.06.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Sokal, Euro and newly developed EUTOS scoring systems were validated in 220 Chinese chronic phase chronic myeloid leukemia (CP-CML) patients treated with frontline imatinib. In the EUTOS low-risk and high-risk groups, the 5-year OS was 98.7% vs. 71.4% (P<0.0001), and the 5-year cumulative incidence of complete cytogenetic response (CCyR) was 92.4% vs. 53.8% (p<0.0001). EUTOS score also predicted progression-free survival and duration of CCyR. Low EUTOS index predicted for CCyR. However, Sokal and Euro scores mainly could not discriminate the intermediate-risk from high-risk group in either survival or CCyR. EUTOS score forecasts the prognosis of CP-CML patients treated with first-line imatinib. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1030 / 1035
页数：6
相关论文
共 50 条
  • [11] Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results
    Palandri, Francesca
    Testoni, Nicoletta
    Luatti, Simona
    Marzocchi, Giulia
    Baldazzi, Carmen
    Stacchini, Monica
    Castagnetti, Fausto
    Breccia, Massimo
    Specchia, Giorgina
    Pane, Fabrizio
    Saglio, Giuseppe
    Martinelli, Giovanni
    Baccarani, Michele
    Rosti, Gianantonio
    LEUKEMIA & LYMPHOMA, 2009, 50 (01) : 114 - 118
  • [12] Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib
    Francis, Jose
    Dubashi, Biswajit
    Sundaram, Rajan
    Pradhan, Suresh Chandra
    Chandrasekaran, Adithan
    MEDICAL ONCOLOGY, 2015, 32 (08)
  • [13] First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia
    Rea, D.
    Etienne, G.
    Nicolini, F.
    Cony-Makhoul, P.
    Johnson-Ansah, H.
    Legros, L.
    Huguet, F.
    Tulliez, M.
    Gardembas, M.
    Bouabdallah, K.
    Rousselot, P.
    Cayuela, J-M
    Guilhot, F.
    Mahon, F-X
    LEUKEMIA, 2012, 26 (10) : 2254 - 2259
  • [14] Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression
    Marktel, S
    Marin, D
    Foot, N
    Szydlo, R
    Bua, M
    Karadimitris, A
    De Melo, VAS
    Kotzampaltiris, P
    Dazzi, F
    Rahemtulla, A
    Olavarria, E
    Apperley, JF
    Goldman, JM
    HAEMATOLOGICA, 2003, 88 (03) : 260 - 267
  • [15] Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy
    Xia, Leiming
    Qian, Wei
    Yang, Mingzhen
    Li, Qingsheng
    Liu, Fei
    Xie, Yanyan
    ONCOTARGETS AND THERAPY, 2015, 8 : 2485 - 2492
  • [16] Second-Line Therapy for Patients With Chronic Myeloid Leukemia Resistant to First-Line Imatinib
    Lau, Anna
    Seiter, Karen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (03) : 186 - 196
  • [17] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Wei, Guoqing
    Rafiyath, Shamudheen
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3
  • [18] A population-based study of chronic myeloid leukemia patients treated with imatinib in first line
    Castagnetti, Fausto
    Di Raimondo, Francesco
    De Vivo, Antonio
    Spitaleri, Antonio
    Gugliotta, Gabriele
    Fabbiano, Francesco
    Capodanno, Isabella
    Mannina, Donato
    Salvucci, Marzia
    Antolino, Agostino
    Marasca, Roberto
    Musso, Maurizio
    Crugnola, Monica
    Impera, Stefana
    Trabacchi, Elena
    Musolino, Caterina
    Cavazzini, Francesco
    Mineo, Giuseppe
    Tosi, Patrizia
    Tomaselli, Carmela
    Rizzo, Michele
    Siragusa, Sergio
    Fogli, Miriam
    Ragionieri, Riccardo
    Zironi, Alessandro
    Soverini, Simona
    Martinelli, Giovanni
    Cavo, Michele
    Vigneri, Paolo
    Stagno, Fabio
    Rosti, Gianantonio
    Baccarani, Michele
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (01) : 82 - 87
  • [19] Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population
    Yahng, Seung-Ah
    Jang, Eun-Jung
    Choi, Soo-Young
    Lee, Sung-Eun
    Kim, Soo-Hyun
    Kim, Dong-Wook
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 100 (02) : 132 - 140
  • [20] Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life
    Molica, Matteo
    Colafigli, Gioia
    Scalzulli, Emilia
    Fegatelli, Danilo Alunni
    Ranieri, Sofia Chiatamone
    Rizzo, Lorenzo
    Diverio, Daniela
    Efficace, Fabio
    Latagliata, Roberto
    Foa, Robin
    Breccia, Massimo
    ANNALS OF HEMATOLOGY, 2019, 98 (08) : 1891 - 1904
12345